PET Imaging for Monitoring Cellular and Immunotherapy of Cancer.

IF 2.6 4区医学 Q3 ONCOLOGY

Cancer journal Pub Date : 2024-05-01 DOI:10.1097/PPO.0000000000000722

Benjamin M Larimer

{"title":"PET Imaging for Monitoring Cellular and Immunotherapy of Cancer.","authors":"Benjamin M Larimer","doi":"10.1097/PPO.0000000000000722","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Cancer immunotherapy, including checkpoint blockade and cellular therapy, has become a cornerstone in cancer treatment. However, understanding the factors driving patient response or resistance to these therapies remains challenging. The dynamic interplay between the immune system and tumors requires new approaches for characterization. Biopsies and blood tests provide valuable information, but their limitations have led to increased interest in positron emission tomography (PET)/computed tomography imaging to complement these strategies. The noninvasive nature of PET imaging makes it ideal for monitoring the dynamic tumor immune microenvironment. This review discusses various PET imaging approaches, including immune cell lineage markers, immune functional markers, immune cell metabolism, direct cell labeling, and reporter genes, highlighting their potential in targeted immunotherapies and cell-based approaches. Although PET imaging has limitations, its integration into diagnostic strategies holds promise for improving patient outcomes and accelerating drug development in cancer immunotherapy.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101150/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PPO.0000000000000722","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: Cancer immunotherapy, including checkpoint blockade and cellular therapy, has become a cornerstone in cancer treatment. However, understanding the factors driving patient response or resistance to these therapies remains challenging. The dynamic interplay between the immune system and tumors requires new approaches for characterization. Biopsies and blood tests provide valuable information, but their limitations have led to increased interest in positron emission tomography (PET)/computed tomography imaging to complement these strategies. The noninvasive nature of PET imaging makes it ideal for monitoring the dynamic tumor immune microenvironment. This review discusses various PET imaging approaches, including immune cell lineage markers, immune functional markers, immune cell metabolism, direct cell labeling, and reporter genes, highlighting their potential in targeted immunotherapies and cell-based approaches. Although PET imaging has limitations, its integration into diagnostic strategies holds promise for improving patient outcomes and accelerating drug development in cancer immunotherapy.

查看原文本刊更多论文

用于监测癌症细胞和免疫疗法的 PET 成像。

摘要：癌症免疫疗法，包括检查点阻断和细胞疗法，已成为癌症治疗的基石。然而，了解患者对这些疗法的反应或耐药性的驱动因素仍具有挑战性。免疫系统与肿瘤之间的动态相互作用需要新的表征方法。活组织检查和血液化验可提供有价值的信息，但由于其局限性，人们对正电子发射断层扫描（PET）/计算机断层扫描成像的兴趣日益浓厚，以补充这些策略。PET 成像的无创特性使其成为监测动态肿瘤免疫微环境的理想选择。本综述讨论了各种 PET 成像方法，包括免疫细胞系标志物、免疫功能标志物、免疫细胞代谢、直接细胞标记和报告基因，强调了它们在靶向免疫疗法和基于细胞的方法中的潜力。尽管 PET 成像有其局限性，但将其纳入诊断策略有望改善患者预后，加快癌症免疫疗法的药物开发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer journal 医学-肿瘤学

CiteScore

3.90

自引率

0.00%

发文量

102

审稿时长

7.5 months

期刊介绍： The Cancer Journal: The Journal of Principles & Practice of Oncology provides an integrated view of modern oncology across all disciplines. The Journal publishes original research and reviews, and keeps readers current on content published in the book Cancer: Principles & Practice of Oncology.